48 assets in Mycosis Fungoides

Therapeutic assets addressing Mycosis Fungoides, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Mycosis Fungoides	National Cancer Institute (NCI)	P4	BBB (78)
(+)-Vincristine Mycosis Fungoides	Virogen Biotechnology Inc.	P4	BBB (78)
Fludarabine Mycosis Fungoides	National Cancer Institute (NCI)	P2	BBB (76)
Dexasone Mycosis Fungoides	City of Hope Medical Center	P2	BBB (72)
Cediranib Mycosis Fungoides	National Cancer Institute (NCI)	P2	BB (71)
Lenalidomide Mycosis Fungoides	City of Hope Medical Center	P2	BB (70)
Brentuximab Vedotin Mycosis Fungoides	University of Alabama at Birmingham	P3	BB (68)
Irinotecan Mycosis Fungoides	Virogen Biotechnology Inc.	P2	BB (67)
VITPSO Mycosis Fungoides	Columbia University	P4	BB (67)
4,5,7,4',5',7'-HEXAHYDROXY-2,2'-DIMETHYLNAPHTHODIANTHRONE Mycosis Fungoides	Soligenix	P3	BB (66)
Pembrolizumab Mycosis Fungoides	Sorrento Therapeutics, Inc.	P2	BB (66)
Mogamulizumab Mycosis Fungoides	Virogen Biotechnology Inc.	P2	BB (65)
Vorinostat Mycosis Fungoides	Virogen Biotechnology Inc.	P2	BB (65)
Bexarotene Mycosis Fungoides	Case Comprehensive Cancer Center	P3	B (63)
Mechlorethamine Mycosis Fungoides	Soligenix	P2	B (63)
Bendamustine Mycosis Fungoides	UNC Lineberger Comprehensive Cancer Center	P2	B (62)
Romidepsin Mycosis Fungoides	Walter Hanel	P2	B (62)
Resminostat Mycosis Fungoides	4SC AG	P2	B (61)
Nivolumab Mycosis Fungoides	National Cancer Institute (NCI)	P2	B (60)
Kenacort Mycosis Fungoides	Case Comprehensive Cancer Center	P2	B (57)
A-Dmdt390-Bisfv(Ucht1) Mycosis Fungoides	Virogen Biotechnology Inc.	P2	CCC (54)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Mycosis Fungoides	National Cancer Institute (NCI)	P2	CCC (53)
Pralatrexate Mycosis Fungoides	City of Hope Medical Center	P1/2	CCC (53)
Tapinarof Mycosis Fungoides	Peking University First Hospital	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Mycosis Fungoides	AHS Cancer Control Alberta	P1/2	CCC (50)
Ritlecitinib Mycosis Fungoides	Icahn School of Medicine at Mount Sinai	P2	CCC (50)
Durvalumab Mycosis Fungoides	City of Hope Medical Center	P1/2	CCC (48)
Parsaclisib Mycosis Fungoides	Walter Hanel	P1	CC (47)
mt-101 Mycosis Fungoides	Myeloid Therapeutics	P1/2	CC (45)
Anti-Icos Monoclonal Antibody Medi-570 Mycosis Fungoides	National Cancer Institute (NCI)	P1	CC (43)
Duvelisib Mycosis Fungoides	National Cancer Institute (NCI)	P1	CC (43)
Wu-Cart-007 Mycosis Fungoides	Washington University School of Medicine	P1	CC (43)
Atlcar.Cd30.Ccr4 Cells Mycosis Fungoides	UNC Lineberger Comprehensive Cancer Center	P1	CC (41)
Autologous Ccr4 Car T Cells Mycosis Fungoides	National Cancer Institute (NCI)	P1	CC (41)
Fenretinide Mycosis Fungoides	SciTech Development, Inc.	P1	CC (41)
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta Mycosis Fungoides	Mayo Clinic	P1	CC (41)
Ruxolitinib Mycosis Fungoides	Mayo Clinic	P1	CC (41)
Tulmimetostat Mycosis Fungoides	Washington University School of Medicine	P1	CC (41)
dt-7012 Mycosis Fungoides	Assistance Publique - Hôpitaux de Paris	Early P1	C (38)
Imiquimod Mycosis Fungoides	Northwestern University	Early P1	C (38)
Nitrogen Mustard Mycosis Fungoides	Case Comprehensive Cancer Center	N/A	D (30)
Chlormethine Mycosis Fungoides	European Organisation for Research and Treatment of Cancer - EORTC	P2	NR ()
Jab-8263 Mycosis Fungoides	Jacobio Pharmaceuticals Co., Ltd.	P1/2	NR ()
vg712 Mycosis Fungoides	Virogen Biotechnology Inc.	P2	NR ()